Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins

Abstract

Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.

1 . A method to purify APOAI from plasma fraction IV,
 1) Fraction IV is resuspended in a buffer with pH 3.00-10.00, and the celite and other impurities were separated by press filter or centrifugation, the resulted supernatant was then collected,   2) The APOAI in the supernatant was then precipitated by adding NaCl and then was spin to collect the paste,   3) The resulted APOAI was then resuspended and filtered,   4) The resulted suspension was then underwent DEAE ion exchanging chromatography and butyl chromatography,   
     
     
         2 . The method of  claim 1 , wherein the fraction IV was resuspended in NaAc buffer with pH 3.00-10.00 
     
     
         3 . The method of  claim 1 , wherein the APOAI was precipitated by NaCl, pH 3.0-10.0, cool down to −1 to 1 C 
     
     
         4 . The method of  claim 3 , the paste of APOAI can be resuspended in WFI or NaCl solution with pH 3.00-10.00 and 0-10 C 
     
     
         5 . The method of  claim 4 , wherein the resulted suspension is filtered with 0.45 um filter. 
     
     
         6 . The method of  claim 1 - 5 , wherein the chromatography in step 4 is Canion (DEAE) and butyl 
     
     
         7 . The method of  claim 6 , the purification of APOAI by chromatography compromising, Canion chromatography, adjust pH of filtered APOAI suspension to 3.0-10.0 and ionic strength to 15-25 mM, load on DEAE chromatography, low salt wash the DEAE chromatography, and then high salt elute the DEAE chromatography, collect the resulted APOAI elute, Butyl chromatography, the resulted APOAI elute from DEAE chromatography is adjusted to pH 3.0-10.0 and low salt wash for impurities, WFI or alkaline buffer wash to collect APOAI enriched elute 
     
     
         8 . The method of  claim 7 , the low salt buffer is a buffer containing Tris with pH 3.00-10.0, the high salt buffer is a buffer containing NaCl, the low salt elute buffer is a buffer containing Tris, the alkaline buffer is a buffer containing NaOH with pH 3.0-10.0 
     
     
         9 . The method of  claim 1 - 8 , the resulted high purity of APOAI is then dialyzed and concentrated with virus inactivation, adding stabilizer and lyophilized. 
     
     
         10 . Resuspension of fraction IV and pretreatment
 1) Fraction IV is resuspended in a buffer with pH 3.00-10.00,   2) The celite and other impurities were separated by press filter of centrifugation; the resulted suspension was then collected,   3) The suspension was then treated with SD virus inactivation,   4) The resulted suspension was then subject to a canion chromatography like DEAE,   5) Proteins were eluted in different fractions,   6) The different eluted fractions were then further purified,   
     
     
         11 . The method of  claim 10 , wherein the fraction IV was dissolved in low temperature buffer to achieve a homogenous suspension, 
     
     
         12 . The method of  claim 10 , wherein the celite in resulted suspension can be removed by press filter or centrifugation, 
     
     
         13 . The method of  claim 10 , wherein the suspension was then cleared by depth filter 
     
     
         14 . The method of  claim 10 , wherein the resulted suspension was then treated with Tween-80 and TNBP for virus inactivation at 25 C for 6 hours, 
     
     
         15 . The method of  claim 10 , wherein the resulted suspension was adjusted pH and ionic strength and then subjected to a canion chromatography like DEAE. The targeted proteins were then binding to the canion chromatography resin, which are transferrin, human albumin, APOAI and A1AT. The 1 st  elution was salt solution to elude the transferrin. The 2 nd  elution was then eluded by a high concentration salt solution, which was APOAI. The 3 rd  eluted fraction was human albumin by a low pH solution. Finally the 4 th  elution was A1AT which was eluted by a high concentration salt solution. 
     
     
         16 . The method of  claim 15 , the resulted various elution was then subjected to different chromatography for further purification to achieve a high purity. The 1 st  elution fraction was subjected to a CM chromatography. The 2 nd  elution fraction was subjected to a butyl chromatography. The 3 rd  elution fraction was subjected to a blue chromatography. The 4 th  elution fraction was subjected to a blue chromatography and a subsequent butyl chromatography. 
     
     
         17 . The method of  claim 16 , the resulted protein fractions were then dialyzed and concentrated. The pH was adjusted and stabilizer was then added. 
     
     
         18 . The method of  claim 17 , the resulted protein solutions were subjected to DV20 filtration for virus removal except human albumin. 
     
     
         19 . The method of  claim 17 , the human albumin could be virus inactivated by pasteurization. 
     
     
         20 . The method of  claim 10 - 19 , the resulted transferrin, APOAI, human albumin and A1AT can be filled. 
     
     
         21 . A protein comprising transferrin, alpha 1-antitrypsin, apolipoprotein A and human albumin which contain of any one of GOOD HEALTHY CELLS like Neutrophil, Lymphocyte, Eosinophil, Basophil Macrophage or any new found Good Healthy cells under investigation. 
     
     
         22 . The protein of  claim 1 , wherein the apolipoprotein comprises of all apoliprotein 
     
     
         23 . A method of treating a human, comprising administering an effective amount of a protein containing transferrin, alpha 1-antitrypsin, apolipoprotein and human albumin. 
     
     
         24 . The method of  claim 6 , wherein the protein is administered by both Intravenous injection and Topical application 
     
     
         25 . The method of  claim 5 , wherein the method is a method of treating numerous diseases and cancers in a human. 
     
     
         26 . The method of  claim 7 , wherein the human has a solid cancer tumor, and the protein is administered by incorporating the protein TOPICALLY in a fibrin sealant and applying the fibrin sealant to the areas where tumor has been removed by surgical operations. 
     
     
         27 . The method of  claim 5 , wherein the method is a method of treating Viruses and bacteria infections in a human. 
     
     
         28 . A method of introduction of HEALTHY GOOD human cells to EAT UP Bad Damaged cells, comprising administering an effective amount of a HEALTHY GOOD protein containing transferin, alpha 1-antitrypsin, apolipoprotein A and human albumin. 
     
     
         29 . A method of reducing damage to healthy human cells, comprising administering an effective amount of a HEALTHY GOOD protein containing ApoA1/2/4 
     
     
         30 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of HEALTHY GOOD protein containing Transferrin 
     
     
         31 . A method of reducing damage to healthy human cells, comprising administering an effective Amount of HEALTHY GOOD protein containing Alpha 1-antitrypsin 
     
     
         32 . A method of reducing damage to healthy human cells, comprising administering an effective amount of HEALTHY GOOD protein containing C1 Esterase Inhibitors and other Inhibitors 
     
     
         33 . A Method of introduction of HEALTHY GOOD human cells to EAT UP Bad damaged cells to reduce damage to healthy human cells, comprising administering an effective amount of a HEALTHY GOOD protein containing Factor II, Factor VII, Factor IX and Factor X in Prothrombin Complex Concentrate (ProthoRAAS®) 
     
     
         34 . A method of reducing damage to healthy human cells, comprising administering an effective amount of a HEALTHY GOOD protein containing Human Albumin (AlbuRAAS®) 
     
     
         35 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of a HEALTHY GOOD protein containing Immunoglobulin (GammaRAAS®) 
     
     
         36 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of a HEALTHY GOOD protein containing Fibrinogen (FibroRAAS®) 
     
     
         37 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of a HEALTHY GOOD protein containing Factor VIII (HemoRAAS®) 
     
     
         38 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of a HEALTHY GOOD protein containing High Concentrate Fibrinogen (FinbrinGluRAAS®) 
     
     
         39 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of a HEALTHY GOOD protein containing Thrombin (ThrombiRAAS®). 
     
     
         40 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of a HEALTHY GOOD protein containing Hepatitis B Immune Globulin (HBIG) (HepaRAAS®) 
     
     
         41 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of a HEALTHY GOOD protein containing Anti thrombin III (AT-III) 
     
     
         42 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of a HEALTHY GOOD protein containing Protein C 
     
     
         43 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of a HEALTHY GOOD protein containing Fibronectin. 
     
     
         44 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of HEALTHY GOOD Protein S. 
     
     
         45 . A Method of reducing damage to healthy human cells, comprising administering an effective Amount of HEALTHY GOOD Protein M 
     
     
         46 . A Method of introduction of HEALTHY GOOD CELLS to EAT UP BAD DAMAGED CELLS to reduce damage to Healthy human cells comprising administering an effective amount of HEALTHY GOOD proteins combined from two to several proteins of the claims. 
     
     
         47 . A Method of introduction of HEALTHY NEW GOOD CELLS to EAT UP BAD DAMAGED CELLS to reduce damage to Healthy Human cells comprising administering an effective amount of all including current and future found HEALTHY GOOD Proteins in Fraction III of Plasma where concentration of HEALTHY GOOD CELLS is MACROPHAGE. 
     
     
         48 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of protein including HEALTHY GOOD CELL MACROPHAGE in white Blood cells, red blood cells, platelets, clyclomicron, electrolyses, peptides in human or in animal or chemicals or substance from any source of materials obtaining by cloning expressing to obtain the cells for further purification by RDNA, Monoclonal, Transgenic, or by any other methodologies. 
     
     
         49 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of protein including HEALTHY GOOD CELL NEUTROPHIL in while Blood cells, red Blood cells, platelets, clyclomicron, electrolyses, peptides in human or in animal or chemicals or substance from any source of materials obtaining by cloning expressing to obtain the cells for further purification by RDNA, Monoclonal, Transgenic or by any other methodologies 
     
     
         50 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of protein including HEALTHY GOOD CELL BASOPHIL in while Blood cells, red Blood cells, platelets, clyclomicron, electrolyses, peptides in human or in animal or chemicals or substance from any source of materials obtaining by cloning expressing to obtain the cells for further purification by RDNA, Monoclonal, Transgenic or by any other methodologies 
     
     
         51 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of protein including HEALTHY GOOD CELL LYMPHOCYTE in while Blood cells, red Blood cells, platelets, clyclomicron, electrolyses, peptides in human or in animal or chemicals or substance from any source of materials obtaining by cloning expressing to obtain the cells for further purification by RDNA, Monoclonal, Transgenic or by any other methodologies. 
     
     
         52 . A Method of reducing damage to healthy human cells, comprising administering an effective amount of protein including HEALTHY GOOD CELL EOSINOPHIL in while Blood cells, red Blood cells, platelets, clyclomicron, electrolyses, peptides in human or in animal or chemicals or substance from any source of materials obtaining by cloning expressing to obtain the cells for further purification by RDNA, Monoclonal, Transgenic or by any other methodologies 
     
     
         53 . A Method of reducing damage to healthy human cells, comprising administering of AT LEAST One HEALTHY GOOD PROTEIN currently found and or new discovered HEALTHY GOOD PROTEINS in the future, and the more HEALTHY GOOD PROTEINS in combination, the MORE POTENT and EFFECTIVE than one HEALTHY GOOD Protein in the treatment of diseases and viruses or bacteria infections. 
     
     
         54 . A Method of inhibition the release of cytokines, including TNF, prevent the activation of HISTONE and TOXICITY produced by Radio/Chemotherapy, comprises administering ONE of Many HEALTHY GOOD PROTEINS 
     
     
         55 . A Method of preventing the loss of HAIR of cancerous patients produced by TOXICITY Caused by Radio/Chemotherapy, comprises administering ONE of Many HEALTHY GOOD PROTEINS. 
     
     
         56 . A Method to prevent the LOSS of TASTE of THROAT CANCER Patients comprises administering ONE of many HEALTHY GOOD PROTEINS. 
     
     
         57 . A method to improve the Human Deficiencies comprises administering ONE of Many HEALTHY GOOD PROTEINS. 
     
     
         58 . A method of repairing, growth and regeneration of MUSCLE comprises administering ONE of many HEALTHY GOOD PROTEINS. 
     
     
         59 . A Method to KILL Enveloped Viruses like HIV1,2 in Blood Products or in any contaminated Product with HIV1,2 comprises administering One of Many HEALTHY GOOD PROTEINS. 
     
     
         60 . A Method to PREVENT and KILL Bacteria in any RDNA/Monoclonal/Chemicals/Plasma Derived Medicinal products comprising administering ONE of many HEALTHY GOOD PROTEINS. 
     
     
         61 . A Method of reducing damage to healthy human cells, comprising of any HEALTHY GOOD PROTEIN in  claims 1  through  52  (AFOD RAAS 1-85, and AFCC RAAS 1-85 can be combined with any current available and future developed DRUGS to ENHANCE the EFFICACY and REDUCE TOXICITY and SIDE EFFECTS caused by Chemical Drugs. 
     
     
         62 . A Method to prevent the LOSS of BREAST from BREAST Cancer Patient by Surgical Operation to remove the Breast Tumor comprises intravenously administering ONE of many HEALTHY GOOD PROTEINS. 
     
     
         63 . A protein comprising at least one of the following apolipoproteins: ApoA1, ApoA2, ApoA4, Apo-B48, ApoB100, ApoCI, ApoCII, ApoCIII, Apo-D, Apo-E, Apo-H, and Apo(a), all of which contain Good Healthy cells. 
     
     
         64 . The protein of  claim 63 , further comprising at least one of the following: Alpha 1 Antitrypsin (A1AT), Transferrin, and Human Albumin, all of which contain Good Healthy cells. 
     
     
         65 . A method of treating a human, comprising administering an effective amount of a protein containing at least one of the following apolipoproteins: ApoA1, ApoA2, ApoA4, Apo-B48, ApoB100, ApoCI, ApoCII, ApoCIII, Apo-D, Apo-E, Apo-H, and Apo(a), all of which contain Good Healthy cells. 
     
     
         66 . The method of  claim 65 , wherein the protein further contains at least one of the following: Alpha 1 Antitrypsin (A1AT), Transferrin, and Human Albumin, all of which contain Good Healthy cells. 
     
     
         67 . A method of introduction of HEALTHY GOOD human cells to EAT UP Bad Damaged cells, comprising administering an effective amount of a protein containing at least one of the following apolipoproteins: ApoA1, ApoA2, ApoA4, Apo-B48, ApoB100, ApoCI, ApoCII, ApoCIII, Apo-D, Apo-E, Apo-H, and Apo(a), all of which contain Good Healthy cells. 
     
     
         68 . The method of  claim 67 , wherein the protein further contains at least one of the following: Alpha 1 Antitrypsin (A1AT), Transferrin, and Human Albumin, all of which contain Good Healthy cells. 
     
     
         69 . A composition for reducing damage to healthy human cells, comprising Prothrombin Complex Concentrate, including all 13 Factors found in Fraction III, Alpha 1 Antitrypsin (A1AT), and Anti thrombin III, all of which contain Good healthy cell proteins. 
     
     
         70 . The protein of  claim 69 , further comprising at least one of the following: Transferrin and Human Albumin, both of which contain Good Healthy cells. 
     
     
         71 . A method of treating a human, comprising administering an effective amount of a composition comprising Prothrombin Complex Concentrate, including all 13 Factors found in Fraction III, Alpha 1 Antitrypsin (A1AT), and Anti thrombin III, all of which contain Good healthy cell proteins. 
     
     
         72 . The method of  claim 71 , wherein the composition further comprises at least one of the following: Transferrin and Human Albumin, both of which contain Good Healthy cells. 
     
     
         73 . A method of treating a human, comprising administering an effective amount of HDL (ApoA1): AFODRAAS 1 (Trade mark) which contain GOOD HEALTHY CELLS 
     
     
         74 . A method of treating a human, comprising administering an effective amount AFODRAAS 2 (Trade Mark) (Human Albumin+ApoA1) both of which contain Good Healthy Cells. 
     
     
         75 . A method of treating a human, comprising administering an effective amount AFODRAAS 3 (Trade Mark) (Intravenous Immuno Globulin (GammaRAAS®+ApoA1), both of which contain Good Healthy Cells. 
     
     
         76 . A method of treating a human, comprising administering an effective amount AFODRAAS 4 (Trade mark) (Factor VIII (HemoRAAS®+ApoA1), both of which contain Good Healthy Cells. 
     
     
         77 . A method of treating a human, comprising administering an effective amount AFODRAAS5 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®+ApoA1), both of which contain Good Healthy Cells. 
     
     
         78 . A method of treating a human, comprising administering an effective amount AFODRAAS6 (Trade mark) (Thrombin (ThrombiRAAS®+ApoA1), both of which contain Good Healthy Cells. 
     
     
         79 . A method of treating a human, comprising administering an effective amount AFODRAAS7 (Trade mark) (Fibrinogen (FibroRAAS®+ApoA1), both of which contain Good Healthy Cells. 
     
     
         80 . A method of treating a human, comprising administering an effective amount AFODRAAS8 (Trade mark) (Fibrin Sealant (FibrinGluRAAS®+ApoA1), both of which contain Good Healthy Cells. 
     
     
         81 . A method of treating a human, comprising administering an effective amount AFODRAAS 9 (Trade mark) (ApoA1+Human Albumin (AlbuRAAS®)+Alpha 1 Anti strepsin (A1AT)+Transferrin), four of which contain Good Healthy Cells. 
     
     
         82 . A method of treating a human, comprising administering an effective amount AFODRAAS 10 (Trade mark) (ApoA1+Human Albumin (AlbuRAAS®)+Alpha 1 Anti Strepsin (A1AT)), four of which contain Good Healthy Cells. 
     
     
         83 . A method of treating a human, comprising administering an effective amount AFODRAAS 11 (Trade mark) (ApoA1+Human Albumin (AlbuRAAS®)+Transferrin), three of which contain Good Healthy Cells. 
     
     
         84 . A method of treating a human, comprising administering an effective amount AFODRAAS 12 (Trade mark) (ApoA1+Alpha 1 Anti Strepsin (A1AT), both of which contain Good Healthy Cells. 
     
     
         85 . A method of treating a human, comprising administering an effective amount AFODRAAS 13 (Trade mark) (ApoA1+Transferrin), both of which contain Good Healthy Cells. 
     
     
         86 . A method of treating a human, comprising administering an effective amount AFODRAAS 14 (Trade mark) (Alpha 1 Anti Strepsin (A1AT)+Transferrin), both of which contain Good Healthy Cells. 
     
     
         87 . A method of treating a human, comprising administering an effective amount AFODRAAS 15 (Trade mark) (Transferrin), which contain Good Healthy Cells. 
     
     
         88 . A method of treating a human, comprising administering an effective amount AFCC RAAS 1 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®)+ApoA1+AT-III), three of which contain Good Healthy Cells. 
     
     
         89 . A method of treating a human, comprising administering an effective amount AFCC RAAS 2 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®)+ApoA1+Human Albumin (AlbuRAAS®)), three of which contain Good Healthy Cells. 
     
     
         90 . A method of treating a human, comprising administering an effective amount AFCC RAAS 3 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®)+ApoA1+Intravenous Immuno Globulin (GammaRAAS®)), three of which contain Good Healthy Cells. 
     
     
         91 . A method of treating a human, comprising administering an effective amount AFCC RAAS 4 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®)+ApoA1+Intravenous Immuno Globulin (GammaRAAS®, +Human Albumin (AlbuRAAS®)), four of which contain Good Healthy Cells. 
     
     
         92 . A method of treating a human, comprising administering an effective amount AFCC RAAS 5 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®)+ApoA1+Intravenous Immuno Globulin (GammaRAAS®, +Human Albumin (AlbuRAAS® and Fibrinogen (FibroRAAS®)), five of which contain Good Healthy Cells. 
     
     
         93 . A method of treating a human, comprising administering an effective amount AFCC RAAS 6 (Trade mark) (Prothombin Complex Concentrate (ProthoRAAS®)+ApoA1+Fibrinogen (FibroRAAS®)), three of which contain Good Healthy Cells. 
     
     
         94 . A method of treating a human, comprising administering an effective amount Protein SEMENOGELIN-1 which contain Good Healthy cells. 
     
     
         95 . A method of treating a human, comprising administering an effective amount Protein HAPTOGLOBIN which contain Good Healthy cells. 
     
     
         96 . A method of treating a human, comprising administering an effective amount Protein VIMENTIN which contain Good Healthy cells. 
     
     
         97 . A method of treating a human, comprising administering an effective amount Protein NESPRIN-2 which contain Good Healthy cells. 
     
     
         98 . A method of treating a human, comprising administering an effective amount Protein INTERFERON A1/13 which contain Good Healthy cells. 
     
     
         99 . A method of treating a human, comprising administering an effective amount Protein INTERFERON Beta which contain Good Healthy cells. 
     
     
         100 . A method of treating a human, comprising administering an effective amount Protein INTERFERON Gamma which contain Good Healthy cells. 
     
     
         101 . A method of treating a human, comprising administering an effective amount Protein HP which contain Good Healthy cells. 
     
     
         102 . A method of treating a human, comprising administering an effective amount Protein VITAMIN D-BINDING which contain Good Healthy cells. 
     
     
         103 . A method of treating a human, comprising administering an effective amount Protein ALPHA-FETOPROTEIN which contain Good Healthy cells. 
     
     
         104 . A method of treating a human, comprising administering an effective amount Protein CASK which contain Good Healthy cells. 
     
     
         105 . A method of treating a human, comprising administering an effective amount Protein AMYLOD PRECURSOR which contain Good Healthy cells. 
     
     
         106 . A method of treating a human, comprising administering an effective amount Protein NEUREXINS which contain Good Healthy cells. 
     
     
         107 . A method of treating a human, comprising administering an effective amount Protein SYNDECANS which contain Good Healthy cells. 
     
     
         108 . A method of treating a human, comprising administering an effective amount Protein G which contain Good Healthy cells. 
     
     
         109 . A method of treating a human, comprising administering an effective amount of any combination ONE or TWO or MORE of proteins which are claimed in this Patent claims, contain Good Healthy cells. 
     
     
         110 . A method of treating a human, comprising administering an effective amount of any combination ONE or TWO or MORE of proteins from any source of animals, human, chemicals, substance, particles, recombinant DNA, Monoclonal, Transgenic containing Good Healthy cells. 
     
     
         111 . A method of treating a human, comprising administering an effective amount of any combination ONE or TWO or MORE of proteins from any source of animals, human, chemicals, substance, particles, recombinant DNA, Monoclonal, Transgenic containing Good Healthy cells which have not been indentified and discovered.